Humanized Mice

General information

PBMC humanized mice are effective model animals for infectious diseases, GvHD, and immuno-oncology. In case of stimulation by mouse xenoantigens, T cells in human-derived PBMCs can proliferate, while other types of cells maintain a low content or die prematurely. The human-derived cells in PBMC humanized mice are mainly T cells, which are suitable for various studies that require T cell immune responses. However, T cells also over-immunize the recipient mice and then trigger graft-versus-host disease (GvHD), which may cause the mice to die after a few weeks. Therefore, PBMC humanized mice have a short window period for tests and are only suitable for short-term studies. The PBMC humanized mice are constructed on the basis of M-NSG-B2m mice but experience the elimination of the B2M β-subunit gene of the MHC class I molecule, which will delay the attack of human immune cells against the host and extend the test window period.


Preparation process


Figure 1. Preparation process of M-NSG mice transplanted with human-derived PBMCs.


Phenotypic analysis


Figure 2. Human-derived CD45+ cell content in peripheral blood of M-NSG mice transplanted with human-derived PBMCs and body weight changes of mice.

Six groups of M-NSG mice were injected with PBMCs from six donors via tail vein, respectively. The overall trend of increased proportion of human-derived CD45+ cells could be detected, with differences in chimerism proportion changes but overall trend as expected. Relatively stable changes in body weight were observed in the mice.

Efficacy evaluation


Figure 3. Anti-tumor efficacy validation in Hu-PBMC H929 tumor-bearing mouse model


Figure 4. Anti-tumor efficacy validation in Hu-PBMC A431 tumor-bearing mouse model

Application field

  • Immuno-oncology study

  • GvHD study

  • Hematological disease study

  • Infectious disease study

  • Gene therapy

  • Study on drug targets without cross reactions

  • Immunogenicity assay

If you need to place an order, please feel free to contact us: 400-728-0660 or

Popular articles

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more
Shanghai Model Organisms Jinshan R&D Base officially put into operation

After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.

Learn more